News
-
-
-
COMMUNIQUÉ DE PRESSE
BRAIN Biotech AG reports half-year figures for fiscal year 2025/26 and confirms full year guidance
BRAIN Biotech AG reports half-year figures for fiscal year 2025/26, with sequential growth in core segment BRAINBiocatalysts and a new European patent for genome editing. Full year guidance confirmed -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Results of the 2026 Annual General Meeting for the 2024/25 financial year of BRAIN Biotech AG
Results of the 2026 Annual General Meeting for the 2024/25 financial year of BRAIN Biotech AG. Shareholders approve all agenda items. New member elected to the Supervisory Board. CEO highlights company's strategy and unique selling points -